Compare Davita Inc (DVA) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Wynn Resorts, Limited — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while Wynn Resorts, Limited trades at $97 (market cap $9.95B). The key difference: Davita Inc is the larger of the two by market cap, and Wynn Resorts, Limited pays a 1.04% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | WYNN | |
|---|---|---|
Market Cap | $14.92B | $9.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $235.71 | $133.34 |
52-Week Low | $103.87 | $94.78 |
Enterprise Value | $27.47B | $20.32B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Wynn Resorts (WYNN) trades at $97.13, down 2.65% today, amid bearish technical signals and recent earnings misses. The stock faces margin pressure despite revenue growth, with net income margin declining to 5.14% in 2025. Analyst consensus remains bullish with a $134.30 price target, though technical indicators show resistance near $99-$103. Recent news highlights Q2 2026 earnings anticipation and luxury segment strength.
Outlook: Long-term potential exists via luxury focus and Macau recovery, but near-term risks include debt load ($10.5B), competitive pressures, and volatile earnings. Investors should weigh high analyst optimism against technical weakness and margin trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
